Levetiracetam Sandoz (Levetiracetam)

Levetiracetam is an antiepileptic agent used to manage seizure disorders.

• Partial‑onset seizures: reduces seizure frequency as adjunctive therapy.
• Generalized tonic‑clonic seizures: provides adjunctive seizure control.
• Myoclonic seizures: helps control myoclonic episodes when added to existing therapy.
• Status epilepticus: administered intravenously for rapid seizure termination.

• Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilizing neuronal membranes. This interaction reduces excessive neuronal firing and diminishes the propagation of epileptic activity, thereby lowering seizure incidence without significant effects on ion channels or G‑protein pathways.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Dizziness: transient feeling of light‑headedness.
• Somnolence: increased sleepiness or fatigue.
• Headache: mild to moderate cranial pain.
• Irritability: mood changes or agitation.
• Nausea: occasional gastrointestinal upset.
• Fatigue: general lack of energy.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Stevens‑Johnson syndrome: rare skin disorder with blistering.
• Suicidal ideation: thoughts of self‑harm.
• Severe depression: marked mood disturbances.
• Blood dyscrasias: abnormal blood counts.
• Respiratory depression: difficulty breathing, especially with concomitant CNS depressants.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

• Renal impairment: adjust dose based on creatinine clearance.
• Psychiatric symptoms: monitor for mood changes, depression, or suicidal thoughts.
• Hypersensitivity: discontinue if rash or anaphylaxis occurs.
• Pregnancy: risk category unknown; weigh benefits against potential risks.
• Discontinuation: avoid abrupt cessation to prevent seizure worsening.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levetiracetam has a relatively low interaction profile, but certain co‑medications may require attention.

Major Interactions (Avoid)

• Concomitant CNS depressants: may increase sedation or respiratory depression.
• Strong enzyme inducers (e.g., carbamazepine, phenytoin, phenobarbital): can markedly reduce levetiracetam plasma levels.

Moderate Interactions (Monitor Closely)

• Other antiepileptic drugs: may require dose adjustments for optimal seizure control.
• Antidepressants or antipsychotics: monitor for additive psychiatric effects.
• Renal‑clearing drugs: assess renal function to avoid accumulation.